• Search
  • Helpdesk
  • Sales contact
Get your demo

Insights from Kayentis clients: why you should choose Kayentis as your eCOA & DCT provider

Project management
Last updated: July 3, 2024

Responsiveness, reliability, professionalism, friendliness… discover why 95.6% of Kayentis clients recommend Kayentis in 2023!

Challenge your eCOA & DCT provider: choose Kayentis for your next clinical trial!

Download the infographic
Follow us on social media
Subscribe to our newsletter
You may also like

Kayentis publishes its first ESG report, strengthening its commitment to...

Kayentis launches interactive eConsent solution to simplify and improve patient...

Better Raters, Smarter eCOA, Stronger Data

Strengthening Endpoint Reliability: An Interview with Estelle Haenel, Chief Medical...

Kayentis and RWS join forces to improve data confidence in...

What if eCOA could elevate your next rare disease trial?

About the author
Picture of Marc Chaperon

Marc Chaperon

Estelle brings 20+ years of experience in pre-clinical and clinical research from Top 5 Pharma and Biotech firms. Leading projects across Phases 1 to 4 in diverse therapeutic areas, she offers deep insights into clinical science, operations, and regulatory intricacies. Appointed as Chief Medical Officer at Kayentis in May 2019.
Meet us at the following events

SCOPE Europe 2026

OCT 13-14 2026 • Barcelona, Spain
Meet our team Chris BARDEN and Björn FELBER at SCOPE Europe Schedule a meeting

ISOQOL 2026

18-21 OCT 2026 • Prague, Czech Republic
33rd Annual Conference | ISOQOL  
Kayentis publishes its first ESG report, strengthening its commitment to responsible and sustainable clinical research
Discover our ESG report, which covers the fiscal year 2025-2026!
  • Read the report